Drugs / Albumin-Bound Paclitaxel
Albumin-Bound Paclitaxel
Trials 38
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06835569 | Mar 2025 → May 2029 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Alterome Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06020885 | Aug 2023 → Oct 2025 overdue | esophageal squamous cell carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06139211 | Jan 2024 → Nov 2025 overdue | neoplasm | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06391190 | Jan 2022 → Dec 2024 overdue | cervical carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04213898 | Jan 2020 → Jan 2021 | triple-negative breast carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04278287 | Oct 2019 → Dec 2025 overdue | esophageal squamous cell carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03994107 | Oct 2019 → Jan 2021 | breast cancer | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 227 trials | ||||||
| Phase 2 | NCT07584031 | Jun 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07601737 | Apr 2026 → Apr 2028 expected | head and neck squamous cell carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07469241 | Mar 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07346807 | Jan → Oct 2026 expected | tongue squamous cell carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06177522 | Nov 2025 → Dec 2027 expected | malignant pancreatic neoplasm | Jinling Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07668453 | Oct 2025 → Jun 2027 expected | biliary tract neoplasm | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07046221 | Aug 2025 → Aug 2027 expected | esophageal squamous cell carcinoma | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06770439 | Apr 2025 → Jan 2027 expected | pancreatic adenocarcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06692491 | Jan 2025 → Dec 2027 expected | — | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06725498 | Dec 2024 → Nov 2026 expected | head and neck squamous cell carcinoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06663059 | Oct 2024 → Dec 2025 overdue | esophageal cancer | Tang-Du Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06599775 | Oct 2024 → Oct 2026 expected | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06487715 | Mar 2024 → Mar 2025 | gastric cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT06222944 | Feb 2024 → Aug 2025 overdue | gastric cancer, gastroesophageal junction adenocarcinoma | Peking University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07266493 | Dec 2023 → Jun 2026 overdue | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06055738 | Oct 2023 → Dec 2026 expected | cervical cancer | Tang-Du Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06028633 | Oct 2023 → Oct 2024 overdue | non-small cell lung carcinoma | Peking University First Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06130332 | Sep 2023 → Aug 2027 expected | oral cavity squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05962021 | Aug 2023 → Jun 2026 | non-small cell lung carcinoma | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06009861 | Jun 2023 → Jun 2026 overdue | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Peking University Hospital of Stomatology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05669807 | Dec 2022 → Nov 2023 | — | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05192798 | Jan 2022 → Sep 2025 overdue | triple-negative breast carcinoma | The First Affiliated Hospital of Bengbu Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05065801 | Jan 2022 → Dec 2026 expected | malignant pancreatic neoplasm | Institut du Cancer de Montpellier - Val d'Aurelle | Recruiting | No outcome recorded |
| Phase 2 | NCT04821765 | Oct 2020 → Jun 2023 | esophageal squamous cell carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04056949 | Aug 2019 → Feb 2021 | small cell lung carcinoma | Junling Li | Unknown | No outcome recorded |
| Phase 2 | NCT04304248 | Aug 2019 → Jul 2026 overdue | non-small cell lung carcinoma | Hao Long | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02754726 | Apr 2016 → Apr 2023 | pancreatic ductal adenocarcinoma | HonorHealth Research Institute | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06647563 | Nov 2024 → Sep 2029 expected | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05429463 | Nov 2022 → Nov 2025 overdue | non-small cell squamous lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07388095 | Feb 2026 → Feb 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05653817 | Jan 2023 → Jan 2025 | cholangiocarcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Comparator or background therapy30 trials | ||||||
| Phase 1 | NCT05979818 Background | Nov 2024 → Aug 2025 overdue | non-small cell lung carcinoma | Second Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| Phase 1 | NCT04336098 Background | Mar 2020 → Aug 2023 | — | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT06939270 Background | May 2025 → May 2027 expected | cancer | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05947487 Background | Jul 2023 → Dec 2025 overdue | cancer | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05693844 Background | Jan 2023 → Dec 2025 overdue | — | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04396821 Background | May 2020 → May 2026 overdue | cancer of unknown primary site, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Suzhou Transcenta Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07581795 Comparator | Jun 2026 → Feb 2029 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07483554 Background | Apr 2026 → Mar 2028 expected | gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07432594 Background | Mar 2026 → May 2027 expected | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07347444 Background | Feb 2026 → Dec 2028 expected | acral lentiginous melanoma, mucosal melanoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07286253 Background | Oct 2025 → Sep 2027 expected | — | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07131514 Background | Aug 2025 → Jun 2027 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07086456 Background | Jul 2025 → Jul 2029 expected | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06682195 Background | Oct 2024 → Oct 2026 expected | triple-negative breast carcinoma | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06532591 Background | Aug 2024 → Apr 2025 overdue | non-small cell lung carcinoma | Sichuan Cancer Hospital and Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06475755 Background | Jun 2024 → Jun 2025 overdue | non-small cell lung carcinoma | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06403111 Background | Jun 2024 → Jun 2026 overdue | non-small cell lung carcinoma | Changzhou No.2 People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06404463 Background | May 2024 → Nov 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06231680 Background | Jan → Jun 2024 | carcinoma of esophagus, non-small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06062485 Background | Oct 2023 → Oct 2025 overdue | carcinoma of the ampulla of vater | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05552651 Background | Sep 2022 → Dec 2023 | esophageal squamous cell carcinoma | Tao Jiang | Unknown | No outcome recorded |
| Phase 2 | NCT05377658 Background | Jul 2022 → Dec 2024 overdue | non-small cell lung carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05322720 Comparator | Apr 2022 → Mar 2023 | cancer | Taizhou EOC Pharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05007145 Background | Aug 2021 → Aug 2023 | esophageal squamous cell carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04446663 Background | Jul 2020 → Dec 2023 | nasopharyngeal carcinoma | First People's Hospital of Foshan | Unknown | No outcome recorded |
| Phase 3 | NCT07648914 Comparator | Jun 2026 → Dec 2028 expected | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07328854 Background | Nov 2025 → Jun 2030 expected | nasopharyngeal carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 4 | NCT06276933 Background | Feb 2024 → Nov 2025 overdue | lung cancer | Tongji University | Not yet recruiting | No outcome recorded |
| — | NCT07552402 Comparator | Jun 2026 → Dec 2027 expected | gastroesophageal junction adenocarcinoma | Harbin Medical University | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 68 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albumin-bound paclitaxel | “with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel...” NCT05962021 ↗67“TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “Investigator-selected chemotherapy includes injectable taxanes (paclitaxel injection, albumin-bound paclitaxel, docetaxel, etc.), irinotecan, etc., excluding oral paclitaxel solution.” NCT07552402 ↗ “Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗ “Enrolled participants received two cycles of induction albumin-bound paclitaxel (260 mg/m2, d1), cisplatin (60 mg/m2, d1), and toripalimab (240 mg, d1) every three weeks” PMID 42028290 ↗ Apr 2026 “Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.” NCT06276933 ↗ “HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab will be administrated per dose level in which the patients are assigned.” NCT07131514 ↗ “Albumin-bound paclitaxel 260 mg/m², carboplatin AUC = 5, intravenous infusion, Day 1, every 3 weeks for 2 cycles.” NCT07584031 ↗ “Albumin bound paclitaxel 125mg / m² followed by Gemcitabine 1000mg / m² followed by 2 weeks of rest” NCT05065801 ↗ “(Note: Gemcitabine can be replaced by docetaxel, albumin-bound paclitaxel, paclitaxel, etc.)” NCT07328854 ↗ “Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W” NCT06475755 ↗ |
| Known as | albumin paclitaxel | “Although data have suggested that antiangiogenic agents may have some benefit to TNBC patients, there seems to be a lack of clinical trials evaluating efficacy and safety of...” NCT05192798 ↗ |
| Known as | Albumin-bound paclitaxel for Injection | “Albumin-bound paclitaxel for Injection” NCT06939270 ↗ |
| Known as | nab-Paclitaxel | “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07668453 ↗2“Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07601737 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07432594 ↗ |
| Route | Intravenous | “125 mg/m2 over 30 minutes IV infusion” NCT02754726 ↗ |